{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:46:05Z","timestamp":1787021165890,"version":"build-2736575974"},"reference-count":121,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.<\/jats:p>","DOI":"10.1200\/edbk_320085","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T15:55:47Z","timestamp":1621007747000},"page":"e246-e265","source":"Crossref","is-referenced-by-count":37,"title":["CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions"],"prefix":"10.1200","author":[{"given":"Saar","family":"Gill","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Brudno","sequence":"additional","affiliation":[{"name":"Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"bibr1-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr2-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"bibr3-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr4-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"bibr5-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr6-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423"},{"key":"bibr7-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr8-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"bibr9-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320"},{"key":"bibr10-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21168-6"},{"key":"bibr11-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813"},{"key":"bibr12-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"bibr13-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710"},{"key":"bibr14-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01892"},{"key":"bibr15-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"bibr16-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"key":"bibr17-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32334-5"},{"key":"bibr18-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"bibr19-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525"},{"key":"bibr20-EDBK_320085","doi-asserted-by":"crossref","unstructured":"Jacobson C, Chavez J, Sehgal A, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood; 2020;136:40-41.","DOI":"10.1182\/blood-2020-136834"},{"key":"bibr21-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"bibr22-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7"},{"key":"bibr23-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"bibr24-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"bibr25-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828343"},{"key":"bibr26-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024"},{"key":"bibr27-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"bibr28-EDBK_320085","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"Tong C","year":"2020","journal-title":"Blood"},{"key":"bibr29-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"bibr30-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122627"},{"key":"bibr31-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03237"},{"key":"bibr32-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"bibr33-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115418"},{"key":"bibr34-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936"},{"key":"bibr35-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"bibr36-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"bibr37-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"bibr38-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004017"},{"key":"bibr40-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"bibr41-EDBK_320085","volume-title":"CD123CAR displays clinical activity in relapsed\/refractory (R\/R) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): safety and efficacy results from a phase 1 study. Cancer Immunol Res","author":"Budde EL","year":"2018"},{"key":"bibr42-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8012"},{"key":"bibr44-EDBK_320085","doi-asserted-by":"crossref","unstructured":"Khurana A, Hathcock M, Habermann T, et al. Lines of therapy before autologous stem cell transplant (ASCT) and CAR-T infusion affect outcomes in aggressive non-Hodgkin\u2019s lymphoma (NHL). Blood. 2020; 136;29-30.","DOI":"10.1182\/blood-2020-142511"},{"key":"bibr45-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003036"},{"key":"bibr46-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"bibr47-EDBK_320085","volume-title":"Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood","author":"Neelapu S","year":"49"},{"key":"bibr48-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"bibr49-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"bibr50-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103"},{"key":"bibr51-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"bibr52-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"bibr54-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"bibr55-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"bibr56-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01616"},{"key":"bibr57-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000515"},{"key":"bibr58-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"bibr59-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"bibr60-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"bibr61-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"bibr62-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"bibr63-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr64-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013"},{"key":"bibr65-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr66-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"bibr67-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"bibr69-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"bibr70-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511"},{"key":"bibr71-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"bibr72-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"bibr73-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"bibr75-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002757"},{"key":"bibr76-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"bibr77-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"bibr78-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"bibr79-EDBK_320085","author":"Strati P","journal-title":"Blood"},{"key":"bibr80-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"},{"key":"bibr81-EDBK_320085","volume-title":"Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma. Blood","author":"Topp MS","year":"243"},{"key":"bibr82-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477"},{"key":"bibr83-EDBK_320085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"Locke FL","year":"2017","journal-title":"Blood"},{"key":"bibr85-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.020"},{"key":"bibr86-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00209-2"},{"key":"bibr87-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295"},{"key":"bibr88-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813"},{"key":"bibr89-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620"},{"key":"bibr90-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"bibr91-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002328"},{"key":"bibr92-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001626"},{"key":"bibr93-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135988"},{"key":"bibr94-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"bibr95-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"bibr96-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1433"},{"key":"bibr97-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"bibr98-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000"},{"key":"bibr99-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.004"},{"key":"bibr100-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"bibr101-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"bibr102-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152"},{"key":"bibr103-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30376-8"},{"key":"bibr104-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002732"},{"key":"bibr105-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003883"},{"key":"bibr106-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.008"},{"key":"bibr107-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"bibr108-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"bibr109-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"bibr110-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814"},{"key":"bibr111-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"bibr112-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"bibr113-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741"},{"key":"bibr114-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"bibr115-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"bibr116-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5"},{"key":"bibr117-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138473"},{"key":"bibr118-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"key":"bibr119-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018883421"},{"key":"bibr120-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002920"},{"key":"bibr121-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3"},{"key":"bibr122-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"bibr123-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307"},{"key":"bibr124-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"bibr125-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01358"},{"key":"bibr126-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081"},{"key":"bibr127-EDBK_320085","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK_320085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T07:16:01Z","timestamp":1672125361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_320085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":121,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1200\/EDBK_320085"],"URL":"https:\/\/doi.org\/10.1200\/edbk_320085","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}